1. Home
  2. NDLS vs FEMY Comparison

NDLS vs FEMY Comparison

Compare NDLS & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

HOLD

Current Price

$11.69

Market Cap

30.7M

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.38

Market Cap

25.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
FEMY
Founded
1995
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.7M
25.6M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
NDLS
FEMY
Price
$11.69
$0.38
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
52.0K
498.3K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.71
EPS
N/A
N/A
Revenue
$495,089,000.00
$2,293,313.00
Revenue This Year
N/A
$105.16
Revenue Next Year
N/A
$200.23
P/E Ratio
N/A
N/A
Revenue Growth
0.37
40.77
52 Week Low
$0.47
$0.31
52 Week High
$12.11
$1.22

Technical Indicators

Market Signals
Indicator
NDLS
FEMY
Relative Strength Index (RSI) 78.29 32.91
Support Level $0.62 $0.37
Resistance Level N/A $0.44
Average True Range (ATR) 0.69 0.03
MACD 0.20 0.00
Stochastic Oscillator 92.42 22.29

Price Performance

Historical Comparison
NDLS
FEMY

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: